High fat programming and cardiovascular disease by Cerf, Marlon E.
medicina
Review
High Fat Programming and Cardiovascular Disease
Marlon E. Cerf 1,2
1 Biomedical Research and Innovation Platform, South African Medical Research Council,
Tygerberg 7505, South Africa; marlon.cerf@mrc.ac.za; Tel.: +27-21-938-0818
2 Division of Medical Physiology, Department of Biomedical Sciences,
Faculty of Medicine and Health Sciences, University of Stellenbosch, Tygerberg 7505, South Africa
Received: 31 August 2018; Accepted: 8 November 2018; Published: 13 November 2018


Abstract: Programming is triggered through events during critical developmental phases that alter
offspring health outcomes. High fat programming is defined as the maintenance on a high fat diet
during fetal and/or early postnatal life that induces metabolic and physiological alterations that
compromise health. The maternal nutritional status, including the dietary fatty acid composition,
during gestation and/or lactation, are key determinants of fetal and postnatal development.
A maternal high fat diet and obesity during gestation compromises the maternal metabolic state
and, through high fat programming, presents an unfavorable intrauterine milieu for fetal growth
and development thereby conferring adverse cardiac outcomes to offspring. Stressors on the heart,
such as a maternal high fat diet and obesity, alter the expression of cardiac-specific factors that alter
cardiac structure and function. The proper nutritional balance, including the fatty acid balance,
particularly during developmental windows, are critical for maintaining cardiac structure, preserving
cardiac function and enhancing the cardiac response to metabolic challenges.
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1. Introduction
1.1. The Programming Concept and Cardiovascular Disease
Programming is triggered through events during critical developmental phases that alter offspring
health outcomes. Fetal programming refers to exposure to a stimulus or insult during fetal (in utero) life.
Lactational programming refers to exposure to a stimulus or insult during early postnatal life i.e., from
birth up to weaning. Developmental programming spans both fetal and lactational programming
i.e., from fetal life up to weaning. Most animal studies focus on either fetal or lactational programming,
the latter can be extended to include childhood. The preconception phase and paternal contribution to
offspring health outcomes are also recognized as forms of programming.
Table 1 summarizes the consequences of fetal programming. There are diverse programming
effects that induce specific metabolic derangements that have been demonstrated across species.
Some programming effects include altered expression profiles of growth, proliferation and circadian
rhythm factors, altered antioxidant enzyme actions, and the induction of increased atherogenesis,
blood pressure, vascular activity and heart rate.
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Table 1. Programming of metabolic disease.
Programming Alterations Species References
Modified mRNA and protein expression of growth, proliferation
and circadian rhythm factors Mice, primates [1–3]
Modified antioxidant enzyme actions Mice [2]
Modified inflammation due to altered mediators and regulators Mice, rabbits [2,4,5]
Modified metabolic glucose and insulin action Mice, rats, humans [2,6–13]
Modified cholesterol synthesis Mice [14]
Increased atherogenesis Mice, rabbits, primates, humans [4,15,16]
Elevated blood pressure and vascular reactivity Mice, rats, sheep [17–21]
Elevated heart rate Mice, sheep [22,23]
Specific programming effects on metabolic derangements are reported in mice, rats, rabbits, sheep, primates and humans.
1.2. Overview of High Fat Programming
Nutrition is a programming stimulus or insult that can typically be low/high protein, carbohydrate
or fat diets, or combinations, administered during specific life stages (i.e., developmental windows) [24].
Maternal nutrition and dietary fatty acid (FA) composition during gestation and/or lactation are key
determinants for normal fetal and postnatal development and contribute to fetal programming effects
that typically influence the offspring’s susceptibility to metabolic diseases over the life course [25]. High
fat programming is defined as the maintenance on a high fat diet (HFD) during fetal and/or early
postnatal life that induces metabolic and physiological alterations that compromise health. Specifically,
high fat programming refers to the exposure of offspring to a high saturated fat diet during fetal
and/or lactational life via maternal nutrition [24]. The HFD is typically high in saturated fat content,
usually ≥40% saturated fat (as energy), that is often derived from animal fat sources. However,
some programming effects can be observed from ≥30% fat (as energy) diet depending on the dietary
constituents. The proportions of the other macronutrients viz. carbohydrates and protein are adjusted
due to the increase in fat content in the diets. However, protein content is usually maintained at
high enough levels i.e., ≥15% protein as energy to avoid the adverse programming effects of protein
deficiency. Glucolipotoxicity refers to the simultaneous elevation of glucose and lipids that results in
intracellular accumulation of lipids and lipid metabolites, with adverse effects on pancreatic [26] and
cardiac structure, function and survival. The exposure of the fetus to hyperglycemia and hyperlipidemia
implicates glucolipotoxicity [27] in the onset of metabolic diseases such as cardiovascular disease (CVD).
1.3. High Fat Programming of Cardiovascular Disease
Cardiac insulin signaling can be impaired due to a shift in FA metabolism resulting in insulin
resistance. A maternal HFD diminishes cardiac function in offspring exposed to diabetic pregnancy
through metabolic abnormalities, oxidative stress and mitochondrial dysfunction [28]. Further, a maternal
HFD compromises organ development and renders the offspring prone to metabolic diseases later in life
including CVD [29]. Maintenance on an HFD during gestation altered the placenta resulting in fetuses
that were either smaller or larger [29]. In rodent models, it was revealed that maternal obesity adversely
impacted the offspring, evident by hypertension, adiposity, hyperphagia, dyslipidemia, insulin resistance
and hepatic steatosis [30–32]. Primates closely mimic human obesity, diabetes and CVD in pathology,
altered glycemia and complications [16]. In primates, HFD maintenance during pregnancy led to broad
developmental health issues in the offspring [3,33–37]. The high fat programming effects in primate
offspring were restricted fetal growth, placental insufficiency with reduced placental blood flow volume,
increased cytokine release, dyslipidemia and increased hepatic fat deposition [3,33–37]. Postnatally,
the offspring maintained on an HFD displayed catch-up growth, increased fat mass and persistent fatty
liver reflecting an increased risk for CVD. In primates, maintenance on an HFD (through maternal feeding
and lactation) impaired offspring vascular function evident by diminished endothelium-dependent
vasodilatation, thickened intima walls, and the onset of inflammation and prothrombosis which
predisposes them to an increased risk of early-onset atherogenesis [16]. Importantly, the vascular function
impairments observed in HFD offspring presented prior to development of obesity [16].
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Prenatal insults that adversely affect fetal growth increase the incidence of hypertension in
adulthood [38–40]. This demonstrates the early initiation of CVD and how it manifests later in life.
The unfavorable intrauterine milieu can induce cardiac derangements that prompt the onset of CVD in
adulthood. Maternal and early postnatal nutrition can alter the trajectories of metabolic and neural
pathways involved in energy homeostasis, linked to the programming of obesity, thereby leading to
disease in adulthood [41].
1.4. Maternal Obesity
Maternal obesity adversely impacts the heart and is associated with CVD in both human and
animal offspring [42]. Offspring of overweight and obese mothers are more susceptible to cardiovascular
anomalies [43], with obesity during pregnancy associated with a higher risk of CVD in adult human
offspring [44]. Further, the programming of hypertension may initiate during intrauterine life; however,
it may also emerge over the offspring’s life course [38]. Low birth weights followed by altered
subsequent growth trajectories (such as catch up growth) contributes to cardiovascular morbidities [38].
Atherosclerosis has a lengthy asymptomatic phase [45] as pathological manifestations emerge in the
arteries of children and young adults, decades prior to overt clinical atherosclerosis [45]. Early life (in utero,
infancy and childhood) nutritional factors determine the progression of atherosclerosis [45]. Maternal
hypercholesterolemia, obesity and diabetes particularly increase CVD risk [39,46] over the life course of
offspring. There are also global changes in fetal lipid and mitochondrial metabolic pathways that predict
later onset metabolic disease, obesity [47] and CVD. The maternal programming influences, viz. maternal
HFD consumption and obesity, are discussed in the context of offspring cardiovascular outcomes.
2. High Fat Programming: Sex-Specificity, Altered Cardiac Gene and microRNA Expression,
and Modified Cardiac Structure and Physiology
2.1. Sex-Specific Influences
Differential sex mechanisms of fetal cardiac programming are caused by an adverse intrauterine
milieu [48] such as high fat programming. In offspring, sex-specific metabolic derangements are
triggered by high fat programming [49], and although conflicting, males are more susceptible to the
programming of CVD [50]. Maternal hyperglycemia in pregnancy is independently associated with
the offspring’s risk for glucose intolerance, obesity and an increase in blood pressure in seven-year-old
children, with only girls being obese [51]. In female sheep, after prenatal bisphenol A (BPA, commonly
found in polycarbonate plastic and epoxy resins) exposure, postnatal overfeeding/adiposity, and the
combination, led to myocardial transcriptional changes, and despite different gene profiles, still
influenced similar signaling pathways [21]. Genes altered by the programming insult were implicated in
obesity, hypertension or heart disease [21]. In rats, a maternal HFD causes cardiac hypertrophy; increases
cardiac susceptibility to ischemic-reperfusion injury only in adult male offspring, and differentially
regulates cardiac angiotensin II (AngII) receptor type 1 (AGTR1) and type 2 (AGTR2) expression [48].
Multiple mechanisms are involved in the sex-specific effects of maternal HFD [48].
2.2. Altered Cardiac Gene and miRNA Expression
AngII, a hormone that regulates blood pressure, and its receptors, viz. AGTR1 and AGTR2, play
key roles in the regulation of cardiovascular homeostasis and are implicated in the fetal programming
of cardio-cerebrovascular diseases [48,52–55]. Further, upregulation of AGTR2 played a causal role in
maternal HFD-induced higher cardiac susceptibility to ischemia-reperfusion injury in male offspring; and
decreased glucocorticoid receptors (GR) binding to glucocorticoid response elements (GREs) at the Agtr2
promoter through HFD-mediated Agtr2 gene upregulation [48]. Therefore, a maternal HFD influences
the expression of key blood pressure regulatory factors that alter cardiac structure and susceptibility to
ischemia-reperfusion injury.
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There is an intricate cardiac miRNA network, modulated by HFD administration, and implicated
in the pathogenesis of CVD. Poor cardiac outcomes are linked to miRNAs modulated after HFD
exposure in mice [56]. In young adult mouse offspring (12 weeks of age), exposure to maternal
obesity altered some cardiac-relevant microRNA (miRNA, small, non-coding endogenous RNAs of
21–25 nucleotides) expression, overlaid on a cardiac miRNAome that was markedly changed after
9 weeks of exposure to a HFD (the HFD mimicked a Western fast-food diet) [56]. After 9 weeks
of the HFD administration, 33 cardiac miRNA expression profiles were altered [56]. miR-30
family members were prominent as their dysregulation is associated with cardiac abnormalities
and ischemia-reperfusion injury [57], cardiomyocyte endoplasmic reticulum (ER) stress [58] and
pathological hypertrophy [59,60]. Diet directly impacts cardiac miR-126 (a negative regulator of
insulin signaling) expression [56] evident by its 2.5-fold upregulation induced by diet-induced
maternal obesity [61]. miR-499 overexpression (>2 fold after HFD exposure) augmented heart
mass and hypertrophy and exacerbated contractile dysfunction [62]. Both miR-24 and miR199a
were overexpressed in failing human hearts, murine cardiac hypertrophy, and induced hypertrophy
in vitro [63]. About two-thirds of miRNAs were diet-upregulated >2 fold in failing hearts [64],
therefore the miRNAs altered by poor nutrition, such as exposure to a HFD in utero, are likely
implicated in poor cardiac health outcomes [56]. miR-208a-3p was upregulated >3 fold by the HFD [56].
The key cardiac-specific miR-208a is required for electrical conduction but its transgenic overexpression
induces hypertrophy [63,65]. Cardiac-specific miR-208a knockdown improves whole-body energy
homeostasis, yielding leaner mice resistant to diet-induced obesity [66]. The alterations in cardiac
miRNA expression profiles by a HFD demonstrates the importance of proper nutrition particularly
during critical developmental periods. Maternal nutrition during gestation and lactation sustains and
shapes offspring growth and therefore the correct healthy balance of nutrients is necessary for positive
offspring development, growth and health outcomes.
The intrauterine milieu can considerably alter fetal genome expression thereby stimulating or
inhibiting fetal growth and adiposity [67]. Downregulation in the miR-17-92 cluster resulted in
septal defects in mice [68] whereas miR-181a plays a role in cardiac neural crest migration [69].
The dysregulation of developmentally key and relevant miRNAs may explain why the offspring of
obese women are more susceptible to several congenital heart defects [70,71]. Differential miRNA
expression, through developmental programming such as maternal high fat feeding and obesity,
therefore influences cardiac development and health outcomes in offspring.
Some miRNA expression altered by a maternal HFD reflected expression profiles in adult
cardiac diseases, such cardiac hypertrophy (miR-21, miR-143 and miR-499) [72], heart failure (miR-21
and miR-223) [73] and myocardial infarction (miR-30c, miR-139 and miR-451) [72]. Overexpressed
miRNAs were implicated in increasing fibrosis (miR-21, miR-499, miRs-30 family and miRs-133
family) [74], intracellular trafficking and cell adhesion (miR-30 family) [59]. Altered cardiac miRNA
expression likely diminishes cardiac function in offspring maintained on a HFD [67]. A maternal HFD,
administered preconception and during gestation, programmed fetal cardiac fibrosis concomitant
with differential cardiac miRNA expression likely implicated in the programming of impaired cardiac
development [67]. Altered miRNA expression, through HFD modulation, therefore alters cardiac
structure with implications on cardiac function and health.
2.3. Modified Cardiac Structure and Physiology
A maternal HFD had no effect on body weight but increased the heart weight and heart
weight-to-body weight in the adult male offspring, which was supported by the echocardiographic
(ECG) analysis showing increased wall thickness and decreased left ventricle internal diameters [48].
Thus, heart weight or its ratio to body weight (independent of body weight), is important as body
weight solely may not alter despite structural and potentially functional cardiac alterations. Further,
a maternal HFD caused cardiomyocyte hypertrophy in adult male offspring rats [48] consistent with
another study reporting that maternal overnutrition during gestation and lactation in mice induced
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cardiac hypertrophy in male offspring [75]. Alterations in the myocardium have also been reported in
a primate model of fetal programming [16]. In rodents, early life overnutrition programmed cardiac
hypertrophy and decreased myocardial vessel density during cardiac development [76]. In addition,
ECG analysis showed that a maternal HFD maintained normal systolic and diastolic function, indicating
that the concentric geometric remodeling with a reduction in left ventricle chamber size relative to wall
thickness is an adaptation to preserve left ventricle pump function [48]. Thus, after maintenance on a
maternal HFD, the heart adapts by remodeling as a compensatory mechanism to maintain function.
However, this may only be temporary as cardiac dysfunction may ensue with a persistent HFD or from
the later effects of programming that present over the life course i.e., adulthood and ageing.
Clinical and experimental studies observed that the perinatal period and early development
milieu regulate metabolic predispositions in adulthood [77] and ageing. Several epidemiological
studies reported that early nutrition may permanently influence body weight trajectories and
cardiometabolic risks viz. hypertension, dyslipidemia and insulin resistance, that render individuals
susceptible to develop CVD [78–82]. Genomic plasticity during neonatal life is necessary for orientating
adult phenotypic traits, since epigenetic modifications may alter gene expression and prompt the
pathogenesis of chronic diseases [77]. In rodents, early overnutrition by decreasing litter size [83,84]
limits competition for milk during lactation thereby resulting in lactational overnutrition [85] which
reflects lactational programming. A reduction in rodent litter size led to a ~30% increase in body
weight at weaning that was maintained as the rodents matured, albeit to a lesser extent [86–88]. Several
metabolic syndrome traits such as overweight, insulin resistance and hypertension were reported in
postnatally overfed rats [83,89]. In adult postnatally overfed rats, impaired cardiac insulin signaling
was demonstrated [90,91] and lactational overnutrition programmed cardiac gene expression, that may
permanently alter cardiac structure and metabolism, impair cardiac contraction and predispose
offspring to myocardial ischemia-reperfusion injury [87,92,93]. Therefore, overnutrition, that often
prompts overweight and obesity, modulates the expression of key cardiac factors, which alters cardiac
structure and function. Neonatal cardiomyocytes exposed to a HFD had lipid droplet accumulation
and mitochondrial hyperplasia with increased oxidative stress (lipid peroxidation) [28]. Neonatal
cardiomyocytes exposed to both a HFD and diabetes presented impaired metabolic fuel flexibility,
mitochondrial dysfunction, and diastolic and systolic dysfunction [28]. The maternal metabolic milieu
therefore shapes and predicts offspring cardiovascular outcomes.
3. Maternal Obesity Triggers Cardiovascular Disease
Obesity encompasses the dysregulation of several molecular pathways and organ systems, including
adipose tissue, pancreas, liver, the central nervous system, gastrointestinal tract and microbiome [94],
and the cardiovascular system. Maternal hyperglycemia increased offspring susceptibility to obesity,
hypertension and glucose intolerance during early childhood; this was independent of maternal obesity,
macrosomia and childhood obesity [51]. Although irregular glucose tolerance levels in children may be
low, the cardiometabolic risk perpetually increases over the life course [51]. A high omega-6/omega-3
ratio is prothrombotic and proinflammatory which fuels the high prevalence of atherosclerosis, diabetes
and obesity [95–100]. HFDs rich in omega-6 FAs increase susceptibility to obesity, leptin resistance and
diabetes in humans and rodents [101,102]. In humans and animals, a high omega-6 FA intake and a
high omega-6/omega-3 ratio stimulate weight gain, whereas a high omega-3 FA intake limits weight
gain [94]. The increasing incidence in obesity is most pronounced during the reproductive ages [103] and,
thus, more children are conceived from overweight/obese parents [56] which contributes to the global
increased incidence and prevalence of obesity. However, early exposure to omega-3 FAs appears favorable
for lipid homeostasis and catalase protein production in offspring during childhood [104]. The maternal
intake of omega-3 FAs in normocaloric and normolipidic diets during gestation and lactation decreased
serum concentrations of triacylglycerol (TAG) and total cholesterol [104]. Therefore, the quality of FAs
influences offspring lipidemia with consequences for cardiometabolic health.
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Both epidemiological and experimental evidence demonstrate that overnutrition during intrauterine
life, often accompanied by obesity, can program susceptibility to metabolic dysfunction in adulthood [105]
and that an adverse intrauterine environment increases the risk for CVD in adulthood [106,107]. These
adverse metabolic effects are genome-independent suggesting that the intrauterine milieu exerts its
influences on offspring susceptibility to metabolic disease [56]. Maternal overweight and obesity are
also considered as important risk factors for adult diseases in offspring, including metabolic disorders,
type 2 diabetes, hypertension and CVD [108–111]. Maternal obesity is associated with various adverse
outcomes for the mother, such as preeclampsia and gestational diabetes [48]. Maternal obesity and HFD
consumption during gestation increase the risk of offspring obesity through complex mechanisms,
which involve metabolic dysregulation and alteration of food intake behavior [112]. Exposure to
maternal adiposity during gestation is linked to offspring with heavier birth weights and greater
adiposity through childhood and over their life course [113]. Developmental overnutrition enables
excessive transplacental passage of nutrients that results in larger babies with greater fat mass [114].
Metabolic dysregulation predisposes to CVD, and in humans, offspring from obese mothers are
predisposed to CVD [44,115]. Animal studies have identified the risk of hypertension [116,117], vascular
dysfunction [118], cardiac hypertrophy and contractile dysfunction [75,119] to all be shaped by maternal
obesity during gestation [56]. Further, maternal obesity during gestation is associated with the adverse
long-term offspring cardiovascular health outcomes, that may be independent of the genome and
adult lifestyle choices [105]. High omega-6 FA intake during the perinatal period contributes to higher
offspring adiposity [94]. Maternal macronutrient (HFD) and micronutrient (FA) profiles shape offspring
cardiovascular outcomes. Maintaining the optimal nutrition to support the pregnant and lactating mothers’
dynamic metabolism is critical to ensure proper development, growth and maturation of their offspring.
4. Maternal High Fat Feeding and Obesity Influences on Offspring Cardiac Outcomes
Figure 1 summarizes the influences of maternal high fat feeding on their offspring’s cardiac outcomes.
Maternal factors, such as malnutrition during gestation, impair myocardial cardioprotection, resulting
in cardiac vulnerability. Glucolipotoxicity, with excess circulating glucose and saturated FAs, induces
adverse cardiac outcomes [120], therefore maintaining an optimal intrauterine milieu is important for the
developing heart. High fat programming often presents a glucolipotoxic milieu, usually co-existing with
maternal obesity, which translates into undesirable consequences for offspring health outcomes. Maternal
hyperglycemia during gestation also independently contributes to the offspring’s risk of hypertension,
glucose intolerance and obesity [51]. Thus, the heart is susceptible to structural and functional changes.
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In the mother, a HFD during gestation induces insulin resistance, inflammation, apoptosis and
cardiac hypertrophy. These unfavorable maternal metabolic derangements, therefore, present an
undesirable intrauterine milieu for fetal development and growth. Hence a maternal HFD confers
undesirable metabolic sequelae to offspring which influences their cardiac outcomes. This occurs
through high fat programming and reflects maternal metabolic conferrance to the fetal offspring.
In these offspring, the mother confers impaired cardiomyocyte hypertrophy and cardiac function
concomitant with obesity. In addition, metabolic abnormalities, oxidative stress and mitochondrial
dysfunction [28] also contribute to offspring cardiac hypertrophy, dysfunction and obesity.
As a maternal HFD and maternal obesity are usually entwined, in the mother, maternal obesity
increases the risk of gestational diabetes, increases cardiovascular anomalies and increases the risk
of preeclampsia reflecting metabolic maternal derangements. Maternal obesity also increases the
inherent risk of hypertension, vascular dysfunction, cardiac hypertrophy and contractile dysfunction
that confers long-term adverse cardiac outcomes to offspring concomitant with obesity.
Thus, the compromised maternal metabolic state during gestation, through maternal HFD
consumption and obesity, programs adverse cardiovascular outcomes in offspring. At birth, offspring
may be equipped with varying abilities to compensate in response to cardiac demand. However, some
offspring may be more susceptible to develop CVD. Hence, prenatal, and later postnatal, nutrition are
also critical periods for shaping offspring health outcomes.
5. Conclusions
Nutrition in pregnancy requires a careful balance of both the quality and quantity of fat intake
to optimize fetal growth and development, also reducing maternal morbidity [121]. The maternal
nutritional status and dietary FA composition during gestation and/or lactation shape offspring
development with high fat programming conferring cardiovascular risk to offspring that may present
at any time over the life course. A well balanced maternal diet during gestation and lactation, with a
favorable FA balance, is therefore critical for good offspring cardiovascular health.
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